AC IMMUNE SA Research and Development Expense
AC IMMUNE SA (ACIU) reported Research and Development Expense of CHF 56.44 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-13
- AC IMMUNE SA research and development expense for the quarter ending 2025-06-30 was 16.83M CHF, a 1.82% decline year-over-year.
- AC IMMUNE SA research and development expense for the quarter ending 2024-06-30 was 17.14M CHF, a 25.26% increase year-over-year.
- AC IMMUNE SA research and development expense for the quarter ending 2023-06-30 was 13.68M CHF, a 12.81% decline year-over-year.
- AC IMMUNE SA research and development expense for the quarter ending 2022-12-31 was 15.14M CHF, a 24.79% decline year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | 56.44M CHF 20-F · filed 2026-03-13 | |||
| 2025-06-30 | 16.83M CHF 6-K · filed 2025-08-05 | 32.74M CHF 6-K · filed 2025-08-05 | ||
| 2024-12-31 | 62.57M CHF 20-F · filed 2026-03-13 | |||
| 2024-06-30 | 17.14M CHF 6-K · filed 2025-08-05 | 32.30M CHF 6-K · filed 2025-08-05 | ||
| 2023-12-31 | 54.61M CHF 20-F · filed 2026-03-13 | |||
| 2023-06-30 | 13.68M CHF 6-K · filed 2024-08-06 | 27.55M CHF 6-K · filed 2024-08-06 | ||
| 2022-12-31 | 15.14M CHF derived: 20-F 12 month − 6-K 9 month · filed 2025-03-13 | 29.52M CHF derived: sum of 2 quarters · filed 2025-03-13 | 45.21M CHF derived: sum of 3 quarters · filed 2025-03-13 | 60.34M CHF 20-F · filed 2025-03-13 |
| 2022-09-30 | 14.38M CHF 6-K · filed 2022-10-28 | 30.08M CHF derived: sum of 2 quarters · filed 2023-08-04 | 45.20M CHF 6-K · filed 2022-10-28 | |
| 2022-06-30 | 15.69M CHF 6-K · filed 2023-08-04 | 30.82M CHF 6-K · filed 2023-08-04 | ||
| 2021-12-31 | 20.12M CHF derived: 20-F 12 month − 6-K 9 month · filed 2024-03-14 | 35.24M CHF derived: sum of 2 quarters · filed 2024-03-14 | 62.28M CHF 20-F · filed 2024-03-14 | |
| 2021-09-30 | 15.12M CHF 6-K · filed 2022-10-28 | 42.16M CHF 6-K · filed 2022-10-28 | ||
| 2020-12-31 | 59.49M CHF 20-F · filed 2023-03-16 | |||
| 2019-12-31 | 50.43M CHF 20-F · filed 2022-03-22 | |||
| 2018-12-31 | 12.13M CHF 20-F · filed 2019-03-21 | 23.68M CHF derived: sum of 2 quarters · filed 2019-03-21 | 34.21M CHF derived: sum of 3 quarters · filed 2019-03-21 | 44.28M CHF 20-F · filed 2021-03-23 |
| 2018-09-30 | 11.55M CHF 20-F · filed 2019-03-21 | 22.08M CHF derived: sum of 2 quarters · filed 2019-03-21 | 32.15M CHF derived: sum of 3 quarters · filed 2019-03-21 | 42.32M CHF derived: sum of 4 quarters · filed 2019-03-21 |
| 2018-06-30 | 10.53M CHF 20-F · filed 2019-03-21 | 20.60M CHF derived: sum of 2 quarters · filed 2019-03-21 | 30.78M CHF derived: sum of 3 quarters · filed 2019-03-21 | 38.97M CHF derived: sum of 4 quarters · filed 2019-03-21 |
| 2018-03-31 | 10.07M CHF 20-F · filed 2019-03-21 | 20.25M CHF derived: sum of 2 quarters · filed 2019-03-21 | 28.44M CHF derived: sum of 3 quarters · filed 2019-03-21 | 35.28M CHF derived: sum of 4 quarters · filed 2019-03-21 |
| 2017-12-31 | 10.18M CHF 20-F · filed 2019-03-21 | 18.37M CHF derived: sum of 2 quarters · filed 2019-03-21 | 25.21M CHF derived: sum of 3 quarters · filed 2019-03-21 | 32.66M CHF 20-F · filed 2020-03-30 |
| 2017-09-30 | 8.20M CHF 20-F · filed 2019-03-21 | 15.03M CHF derived: sum of 2 quarters · filed 2019-03-21 | 22.49M CHF derived: sum of 3 quarters · filed 2019-03-21 | |
| 2017-06-30 | 6.84M CHF 20-F · filed 2019-03-21 | 14.29M CHF derived: sum of 2 quarters · filed 2019-03-21 | ||
| 2017-03-31 | 7.45M CHF 20-F · filed 2019-03-21 | |||
| 2016-12-31 | 25.77M CHF 20-F · filed 2019-03-21 | |||
| 2015-12-31 | 17.05M CHF 20-F · filed 2018-03-20 |